Physician profile
Robert Ruben
NPI 1457354565
$35,521.86
in general payments reported to CMS, 2019-2025
36 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,089 · 2021: $752 · 2022: $4,323 · 2023: $8,940 · 2024: $978 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,225 · Food and Beverage: $2,755 · Travel and Lodging: $950 · Education: $23.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,225.00 |
| Food and Beverage | $2,755.16 |
| Travel and Lodging | $949.62 |
| Education | $23.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28,881.81 | 2019-2025 | |
| Abbvie INC. | $1,533.06 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $734.94 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $644.87 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $490.30 | 2019-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $456.72 | 2019-2024 | Spyglass, Exalt Model D |
| Allergan, INC. | $251.97 | 2019-2020 | |
| Gilead Sciences, INC. | $233.12 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $204.64 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $198.72 | 2019-2024 | Dificid |
| Ucb, INC. | $168.46 | 2019-2020 | |
| Celgene Corporation | $159.38 | 2022-2024 | Zeposia |
| Genzyme Corporation | $144.74 | 2022-2025 | |
| Medtronic, INC. | $131.65 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $129.31 | 2019-2025 | Ocaliva |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $123.29 | 2019-2024 | Rebyota |
| Shire North American Group INC | $98.55 | 2019 | |
| Madrigal Pharmaceuticals | $98.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $80.76 | 2021-2024 | Linzess |
| Daiichi Sankyo INC. | $77.85 | 2020-2024 | Injectafer |
| Amgen INC. | $65.39 | 2020-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $61.61 | 2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $60.70 | 2021-2023 | |
| Braintree Laboratories, INC. | $60.49 | 2019-2021 | |
| Exact Sciences Corporation | $52.18 | 2025 | The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $49.93 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.45 | 2023 | Cyltezo |
| Lilly USA, LLC | $47.36 | 2023-2025 | Omvoh |
| Ambu INC. | $43.91 | 2021 | |
| Shionogi INC | $38.62 | 2019 | |
| Redhill Biopharma INC. | $34.55 | 2020-2021 | |
| Ardelyx, INC. | $34.41 | 2025 | Ibsrela |
| Celltrion USA INC. | $23.14 | 2024 | Zymfentra |
| Organon LLC | $22.19 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.35 | 2024 | Iqirvo |
| Mauna Kea Technologies, INC. | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ruben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.